Ponatinib is recommended, within its marketing authorisation, as an option for treating chronic‑, accelerated‑ or blast‑phase chronic myeloid leukaemia in adults when:
the disease is resistant to dasatinib or nilotinib or
they cannot tolerate dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or
the T315I gene mutation is present.
Ponatinib is recommended, within its marketing authorisation, as an option for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults when:
the disease is resistant to dasatinib or
they cannot tolerate dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate or
the T315I gene mutation is present.
Ponatinib is recommended only if the company provides the drug with the discount agreed in the patient access scheme.